Cancer Database Query Results

NA, Not Available: Click to Expand ⟱
none (reserved)

Scientific Papers found: Click to Expand⟱
2433- 2DG,    Hexokinase inhibitor 2-deoxyglucose coordinates citrullination of vimentin and apoptosis of fibroblast-like synoviocytes by inhibiting HK2 /mTORC1-induced autophagy
- in-vitro, Arthritis, NA - in-vivo, NA, NA
Vim↓, HK2↓,
2432- 2DG,    Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth
- in-vitro, Lung, H23 - in-vitro, Lung, KP2 - in-vivo, NA, NA
HK2↓, Apoptosis↑, TumAuto↑, TumCG↓,
5263- 3BP,  CET,    3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis
- in-vitro, CRC, DLD1 - NA, NA, HCT116
Synergy↑, Ferroptosis↓, TumAuto↑, Apoptosis↑, FOXO3↑, AMPKα↑, p‑Beclin-1/ATG6↑, HK2↓, ATP↓, ROS↑, Dose↝, TumVol↓, TumW↓, xCT/SLC7A11↑, GSH↓, eff↓, MDA↑,
1097- AG,    Astragalus Inhibits Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelial Cells by Down-Regulating β-Catenin
- in-vitro, Nor, HMrSV5 - in-vivo, NA, NA
*EMT↓, *E-cadherin↑, *α-SMA↓, *Vim↓, *β-catenin/ZEB1↓, *Smad7↑,
4557- AgNPs,    The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells
- in-vitro, NA, NIH-3T3 - in-vitro, CRC, HCT116
Cyt‑c↑, ROS↑, JNK↑,
4573- AgNPs,    Bioactive silver nanoparticles derived from Carica papaya floral extract and its dual-functioning biomedical application
- in-vitro, Var, MCF7 - NA, NA, HEK293
toxicity↓, Bacteria↓, selectivity↑,
4362- AgNPs,    Enhancing Colorectal Cancer Radiation Therapy Efficacy using Silver Nanoprisms Decorated with Graphene as Radiosensitizers
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vivo, NA, NA
eff↑, TumCG↓, OS↑, RadioS↑, eff↑, ROS↑, DNAdam↑, eff↝,
374- AgNPs,    Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
ER Stress↑, DNAdam↑, ROS↑, Apoptosis↑, GSH/GSSG↓, NADPH/NADP+↓, TumCG↓, UPR↑,
355- AgNPs,    Cytotoxicity and Genotoxicity of Biogenic Silver Nanoparticles in A549 and BEAS-2B Cell Lines
- in-vitro, Lung, A549 - in-vitro, NA, BEAS-2B
ROS↑, DNAdam↑, Apoptosis↑,
375- AgNPs,  ALA,    Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer
- in-vitro, PC, Bxpc-3 - in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
mtDam↑, ROS↑, *toxicity↓, Dose∅, selectivity↑,
2538- AgNPs,  SDT,  Z,    Dual-functional silver nanoparticle-enhanced ZnO nanorods for improved reactive oxygen species generation and cancer treatment
- Study, Var, NA - vitro+vivo, NA, NA
ROS↑, eff↑, eff↑, TumCP↓, toxicity↓,
1023- AL,    Allicin May Promote Reversal of T-Cell Dysfunction in Periodontitis via the PD-1 Pathway
- in-vitro, Var, NA - Analysis, NA, NA
PD-L1↓,
251- AL,    Inhibition of allicin in Eca109 and EC9706 cells via G2/M phase arrest and mitochondrial apoptosis pathway
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706 - in-vivo, NA, NA
Apoptosis↑, P53↑, P21↑, CHK1↑, CycB/CCNB1↓, BAX↑, Casp3↑, Casp9↑, Cyt‑c↑,
1235- ALA,  Cisplatin,    α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway
- in-vitro, Nor, HEI-OC1 - ex-vivo, NA, NA
ROS↑, HO-1↓, *toxicity↓, chemoP↑, *ROS↓, *HO-1↑, *SOD1↑, *NRF2↑,
3438- ALA,    The Potent Antioxidant Alpha Lipoic Acid
- Review, NA, NA - Review, AD, NA
*antiOx↑, *cardioP↑, *cognitive↑, *AntiAge↑, *Inflam↓, *AntiCan↑, *neuroP↑, *IronCh↑, *ROS↑, *Weight↓, *Ach↑, *ROS↓, *GSH↑, *lipid-P↓, *memory↑, *NRF2↑, *ChAT↑, *GlucoseCon↑, *Acetyl-CoA↑,
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
1123- aLinA,    Linoleic acid induces an EMT-like process in mammary epithelial cells MCF10A
- in-vitro, BC, NA - in-vitro, NA, MCF10
TumCP↑, E-cadherin↓, Snail↑, Twist↑, ZEB2↑, FAK↑, NF-kB↑, MMP2↓, MMP9↓, *EMT↑, TumCI↑,
1348- And,    Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
- in-vitro, BC, MCF7 - in-vitro, BC, T47D - in-vivo, NA, NA
ERα/ESR1↓, TumCG↓, ROS↑, FOXM1↓, Synergy↑,
1151- Api,    Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study
- in-vitro, Pca, PC3 - in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
TumCCA↑, Apoptosis↑, HDAC↓, P21↑, BAX↑, TumCG↓, Bcl-2↓, Bax:Bcl2↑, HDAC1↓, HDAC3↓,
1999- Api,  doxoR,    Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation
- in-vitro, Nor, NRK52E - in-vitro, Nor, MPC5 - in-vitro, BC, 4T1 - in-vivo, NA, NA
neuroP↑, ChemoSen∅, RenoP↑, selectivity↑, chemoP↑, ROS↑, *ROS∅, *antiOx↑, *toxicity↓,
1564- Api,    Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation
- in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
MDM2↓, NF-kB↓, p65↓, P21↑, ROS↑, GSH↓, MMP↓, Cyt‑c↑, Apoptosis↑, P53↑, eff↓, Bcl-xL↓, Bcl-2↓, BAX↑, Casp↑, TumCG↓, TumVol↓, TumW↓,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, Synergy↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
3392- ART/DHA,    Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways
- in-vitro, Nor, Hep3B - in-vivo, NA, NA
*Inflam↓, *NF-kB↓, *ROS↓, *p‑p38↓, *p‑ERK↓,
2576- ART/DHA,  AL,    The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo
- in-vitro, OS, MG63 - in-vivo, NA, NA
Synergy↑, tumCV↓, Casp3↑, Casp9↑, Apoptosis↑, TumCG↓,
568- ART/DHA,    Mechanism-Guided Design and Synthesis of a Mitochondria-Targeting Artemisinin Analogue with Enhanced Anticancer Activity
- Study, Var, MDA-MB-231 - in-vitro, NA, HeLa - in-vitro, NA, SkBr3 - in-vitro, NA, HCT116
Iron↝,
985- ART/DHA,    Artemisinin suppresses aerobic glycolysis in thyroid cancer cells by downregulating HIF-1a, which is increased by the XIST/miR-93/HIF-1a pathway
- in-vitro, Thyroid, TPC-1 - Human, NA, NA
XIST↓, Hif1a↓, Glycolysis↓, TumCCA↑, TumMeta↓,
1304- ASA,    Aspirin Inhibits Colorectal Cancer via the TIGIT-BCL2-BAX pathway in T Cells
- in-vitro, CRC, NA - in-vivo, NA, NA
TumCP↓, Apoptosis↑, Bcl-2↓, BAX↑, IL10↓, LTA/TNF-β↓,
1360- Ash,  immuno,    Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
- in-vitro, Lung, H1650 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP/DDIT3↑, p‑eIF2α↑, ICD↑, eff↑,
1363- Ash,  doxoR,    Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, CaOV3 - in-vivo, NA, NA
ChemoSen↑, ROS↑, DNAdam↑, TumCCA↑, LC3B↑, TumCG↓, cl‑Casp3↑,
1179- Ash,    Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCP↓, TumCMig↓, STAT3↓, TumVol↓, TumW↓,
1178- Ash,    Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor
- in-vitro, Nor, HUVECs - in-vivo, NA, NA
*VEGF↓, *angioG↓, *ascitic↓, *Sp1/3/4↓,
1172- Ash,    Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
FASN↓, ACLY↓, ACC1↓, CPT1A↓, SREBP1/SREBF1↓,
3170- Ash,    Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms
- in-vitro, Nor, NRK52E - in-vivo, NA, NA
*RenoP↑, *hepatoP↑, *creat↓, *BUN↓, *uricA↓, *Apoptosis↓, *α-SMA↓,
4808- ASTX,    Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer
- in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, STAT3↓, Apoptosis↑, TumCMig↓, TumCI↓,
1098- BA,    Baicalein inhibits fibronectin-induced epithelial–mesenchymal transition by decreasing activation and upregulation of calpain-2
- in-vitro, Nor, MCF10 - in-vivo, NA, NA
*TumCMig↓, *F-actin↓, *E-cadherin↑, *ZO-1↑, *N-cadherin↓, *Vim↓, *Snail↓, *cal2↓, *Ca+2↝,
2475- Ba,    Baicalein triggers ferroptosis in colorectal cancer cells via blocking the JAK2/STAT3/GPX4 axis
- in-vitro, CRC, HCT116 - in-vitro, CRC, DLD1 - in-vivo, NA, NA
tumCV↓, GPx4↓, STAT3↓, Ferroptosis↑,
2599- Ba,    Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCP↓, Apoptosis↑, p‑Akt↓, p‑mTOR↓, NF-kB↓, p‑IKKα↓, IKKα↑, PI3K↓, MMP↓, TumAuto↑, TumVol↓, TumW↓,
2293- Ba,    Baicalein suppresses inflammation and attenuates acute lung injury by inhibiting glycolysis via HIF‑1α signaling
- in-vitro, Nor, MH-S - in-vivo, NA, NA
*Hif1a↓, *Glycolysis↓, *Inflam↓, *HK2↓, *PFK1↓, *PKM2↓,
1375- BBR,    13-[CH2CO-Cys-(Bzl)-OBzl]-Berberine: Exploring The Correlation Of Anti-Tumor Efficacy With ROS And Apoptosis Protein
- in-vitro, CRC, HCT8 - in-vivo, NA, NA
ROS↑, TumCP↓, XIAP↓, TumCG↓, *toxicity↓,
2335- BBR,    Chemoproteomics reveals berberine directly binds to PKM2 to inhibit the progression of colorectal cancer
- in-vitro, CRC, HT29 - in-vitro, CRC, HCT116 - in-vivo, NA, NA
PKM2↓, Glycolysis↓, p‑STAT3↓, Bcl-2↓, cycD1/CCND1↓, TumCG↓, Ki-67↓, lactateProd↓, glucose↓,
2692- BBR,    Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis
- in-vitro, OS, MG63 - in-vitro, OS, SaOS2 - in-vivo, NA, NA
Casp1↓, IL1β↓, TumCG↓, Dose↝, Apoptosis↑, Inflam↓,
2712- BBR,    Suppression of colon cancer growth by berberine mediated by the intestinal microbiota and the suppression of DNA methyltransferases (DNMTs)
- in-vitro, Colon, HT29 - in-vivo, NA, NA
TumCG↓, GutMicro↑, other↝, IL10↓, cMyc↓, DNMT1↓, DNMTs↓,
2706- BBR,    Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake
- in-vitro, HCC, Hep3B - in-vitro, HCC, Bel-7402 - in-vivo, NA, NA
TumCP↓, glut↓, SLC12A5↓, cMyc↓, GLS↓,
2711- BBR,    Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, FGF↓, IGFBP3↑,
943- BetA,    Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
Glycolysis↓, lactateProd↓, GlucoseCon↓, ECAR↓, cMyc↓, LDHA↓, p‑PDK1 / PDPK1↓, PDK1 / PDPK1↓, Cav1↑, *Glycolysis↑, selectivity↑, OCR↓, OXPHOS↓,
2733- BetA,    Betulinic Acid Inhibits Cell Proliferation in Human Oral Squamous Cell Carcinoma via Modulating ROS-Regulated p53 Signaling
- in-vitro, Oral, KB - in-vivo, NA, NA
TumCP↓, TumVol↓, mt-Apoptosis↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↑, OCR↓, TumCCA↑, ROS↑, eff↓, P53↑, STAT3↓, cycD1/CCND1↑,
2738- BetA,    Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
TumCI↓, TumCMig↓, Glycolysis↓, lactateProd↓, GRP78/BiP↑, ER Stress↑, PERK↑, p‑eIF2α↑, β-catenin/ZEB1↓, cMyc↓, ROS↑, angioG↓, Sp1/3/4↓, DNAdam↑, TOP1↓, TumMeta↓, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, LDHA↓, p‑PDK1 / PDPK1↓, PDK1 / PDPK1↓, ECAR↓, OCR↓, Hif1a↓, STAT3↓,
2741- BetA,    Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress
- in-vitro, GC, SNU16 - in-vitro, GC, NCI-N87 - in-vivo, NA, NA
TumCG↓, TumCMig↓, TumCI↓, N-cadherin↓, E-cadherin↑, EMT↓, Ki-67↓, MMP2↓,
2745- BetA,    Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors
- in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vivo, NA, NA
Apoptosis↑, TumCG↓, Sp1/3/4↓, survivin↓, VEGF↓, p65↓, EGFR↓, cycD1/CCND1↓, ROS↑, MMP↓,
9161- BITC,    Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vitro, NA, MCF10
TumCG↓, TumCCA↑, Apoptosis↑, selectivity↑, CycB/CCNB1↓, CDK1↓, CDC25↓, BAX↑, Bcl-2↓, Bcl-xL↓, MMP↓, Cyt‑c↑, ROS?, cl‑Casp9↑, cl‑Casp8↑, cl‑Casp3↑,

Showing Research Papers: 1 to 50 of 206
Page 1 of 5 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 206

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Fenton↑, 2,   GPx4↓, 3,   GSH↓, 9,   GSH/GSSG↓, 1,   H2O2↑, 5,   e-H2O2↓, 1,   i-H2O2∅, 1,   HO-1↓, 1,   Iron↑, 2,   Iron↝, 1,   ox-Keap1↓, 1,   rd-Keap1↑, 1,   MDA↑, 1,   NADPH/NADP+↓, 1,   NQO1?, 1,   NRF2↓, 2,   NRF2∅, 1,   Prx4↓, 1,   ROS?, 2,   ROS↓, 4,   ROS↑, 58,   i-ROS↑, 2,   mt-ROS↑, 3,   SOD↑, 1,   SOD2↑, 1,   Trx↓, 1,   xCT/SLC7A11↓, 3,   xCT/SLC7A11↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC25↓, 2,   compI↓, 1,   compII↓, 1,   mitResp↓, 1,   mtDam↑, 6,   OCR↓, 6,   OCR↑, 2,   OXPHOS↓, 1,   OXPHOS↑, 2,   mt-OXPHOS↑, 1,   PGC-1α↑, 1,   PINK1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 2,   ACC1↓, 2,   ACLY↓, 1,   ALAT∅, 1,   AminoA↓, 1,   AMP↑, 1,   AMPK↑, 6,   p‑AMPK↑, 1,   ATP↓, 6,   ATP↑, 1,   ATP:AMP↓, 1,   CPT1A↓, 2,   ECAR↓, 6,   ECAR∅, 1,   FABP4↑, 1,   FASN↓, 3,   GLS↓, 1,   glucose↓, 1,   GlucoseCon↓, 14,   glut↓, 1,   Glycolysis↓, 26,   GSK‐3β↑, 1,   HK2↓, 15,   HK2∅, 1,   IDH1↑, 1,   lactateProd↓, 17,   LDHA↓, 9,   LDHA∅, 1,   NAD↓, 1,   NADPH↑, 1,   p‑PCK1↓, 1,   PDK1 / PDPK1↓, 2,   p‑PDK1 / PDPK1↓, 2,   PDKs↓, 1,   PFK↓, 2,   PFK1↓, 2,   PFKP↓, 2,   PKM2↓, 17,   PKM2∅, 1,   p‑PKM2↓, 1,   SIRT1↓, 1,   SIRT2↓, 1,   SREBP1/SREBF1?, 1,   SREBP1/SREBF1↓, 1,   TCA↓, 1,   Warburg↓, 6,   β-oxidation↓, 1,  

Cell Death(tgid=5) ⓘ

AIF↑, 1,   APAF1↑, 1,   Apoptosis?, 1,   Apoptosis↑, 57,   mt-Apoptosis↑, 1,   BAD↓, 1,   BAD↑, 3,   Bak↑, 1,   BAX↑, 20,   Bax:Bcl2↑, 2,   Bcl-2↓, 25,   Bcl-2↑, 1,   Bcl-xL↓, 8,   BIM↑, 1,   BNIP3↑, 1,   BNIP3↝, 1,   Casp↑, 5,   Casp1↓, 2,   cl‑Casp1↑, 1,   Casp12↑, 1,   Casp3?, 1,   Casp3↑, 17,   cl‑Casp3↑, 7,   proCasp3↑, 1,   Casp7?, 1,   Casp7↑, 2,   Casp8↑, 3,   cl‑Casp8↑, 1,   Casp9?, 1,   Casp9↑, 12,   cl‑Casp9↑, 1,   Cyt‑c↑, 14,   Cyt‑c↝, 1,   DR5↑, 1,   Ferroptosis↓, 1,   Ferroptosis↑, 3,   cl‑GSDMD↑, 1,   GSDME-N↑, 2,   IAP1↓, 1,   ICD↑, 1,   iNOS↓, 1,   Mcl-1↓, 1,   MDM2↓, 1,   MLKL↑, 1,   p‑MLKL↓, 1,   Necroptosis↑, 4,   p38↑, 1,   p‑p38↓, 1,   p‑p38↑, 2,   Paraptosis↑, 1,   Pyro↑, 3,   RIP3↑, 3,   p‑RIP3↑, 1,   survivin↓, 8,   TumCD↑, 6,   TUNEL↑, 1,   XIAP↓, 4,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 15,   Akt↑, 1,   p‑Akt↓, 6,   AMPKα↑, 1,   cMET↓, 1,   EGFR↓, 5,   ERK↓, 2,   ERK↑, 2,   p‑ERK↓, 3,   p‑ERK↑, 2,   ERK5↑, 1,   IGF-1R↓, 2,   p‑IGF-1R↓, 1,   IKKα↑, 2,   p‑IKKα↓, 1,   JAK2↓, 3,   JNK↑, 4,   p‑JNK↑, 4,   MAPK↓, 2,   MAPK↑, 3,   mTOR↓, 10,   mTOR↑, 3,   p‑mTOR↓, 1,   p‑p70S6↓, 1,   PI3K↓, 11,   p‑PI3K↓, 1,   PKA↓, 2,   PTEN↑, 5,   RIP1↑, 2,   Sp1/3/4↓, 5,   c-Src↓, 1,   STAT3↓, 13,   STAT3↑, 1,   p‑STAT3↓, 5,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↑, 3,   cMyc↓, 10,   DNMT1↓, 3,   DNMT3A↓, 1,   DNMTs↓, 1,   FOXM1↓, 1,   FOXO1↑, 1,   FOXO3↓, 1,   FOXO3↑, 1,   ac‑H3↑, 2,   ac‑H4↑, 2,   HATs↓, 1,   HDAC↓, 7,   HDAC1↓, 2,   HDAC2↓, 1,   HDAC3↓, 2,   HDAC4↓, 1,   HDAC8↓, 1,   miR-139-5p↑, 1,   miR-200b↑, 1,   miR-200c↑, 1,   OCT4↓, 1,   other↓, 1,   other↑, 2,   other↝, 2,   PRMT6↓, 1,   sonoS↑, 1,   SOX2↓, 1,   tumCV?, 1,   tumCV↓, 25,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1,   CHOP/DDIT3↑, 6,   CRT↑, 1,   eIF2α↑, 3,   p‑eIF2α↑, 5,   ER Stress↑, 13,   GRP78/BiP↑, 4,   p‑Hsc70↑, 1,   HSP70/HSPA5↓, 2,   HSP70/HSPA5↑, 1,   HSP90↓, 2,   HSP90↑, 1,   PERK↓, 1,   PERK↑, 4,   Proteasome↓, 1,   UPR↑, 4,   mt-UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   ATG7↑, 1,   Beclin-1/ATG6↑, 1,   p‑Beclin-1/ATG6↑, 1,   LC3B↑, 2,   LC3B-II↑, 2,   LC3II↑, 3,   p62↓, 2,   p62↑, 2,   PARK2↑, 1,   TumAuto↑, 12,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 14,   NKX3.1↓, 1,   P53?, 1,   P53↓, 1,   P53↑, 11,   P53↝, 1,   p‑P53↓, 1,   p‑P53↑, 2,   PARP↑, 2,   p‑PARP↑, 1,   cl‑PARP↑, 7,   PCNA↓, 1,   TOP1↓, 1,   TOP2↓, 1,   TP53↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↓, 1,   CDK4↓, 1,   CDK6↓, 1,   CHK1↑, 1,   Chk2↑, 1,   p‑Chk2↑, 1,   CycB/CCNB1↓, 2,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 14,   cycD1/CCND1↑, 1,   cycE/CCNE↓, 2,   E2Fs↓, 1,   Ki-67↓, 6,   P21↑, 10,   p27/CDKN1B↑, 1,   TumCCA↑, 26,   UBE2C↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   BMI1↓, 1,   CD133↓, 2,   CD24↓, 2,   CSCs↓, 6,   Diff↑, 3,   FGF↓, 1,   Gli1↓, 2,   GTPBP4↓, 1,   IGF-1↓, 1,   IGFBP3↓, 1,   IGFBP3↑, 1,   Ki-67↓, 6,   Let-7↑, 2,   LRP6↓, 1,   Nanog↓, 2,   Nestin↓, 2,   NOTCH1↝, 1,   Shh↓, 1,   TumCG↓, 59,   TumCG↑, 1,   TumCP↓, 41,   TumCP↑, 1,   Wnt↓, 4,  

Migration(tgid=13) ⓘ

AP-1↝, 1,   Ca+2↑, 3,   Cav1↑, 1,   CCN2/CTGF↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 16,   EMT?, 1,   EMT↓, 17,   FAK↓, 2,   FAK↑, 1,   Fibrosis↓, 1,   hnRNPA1↓, 1,   ITGA5↓, 1,   ITGB1↓, 1,   LEF1↓, 1,   MALAT1↓, 1,   MET↑, 1,   MMP2↓, 7,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 9,   N-cadherin↓, 6,   Rho↓, 1,   SDC1↑, 1,   Slug↓, 3,   p‑SMAD2↓, 1,   Snail↓, 7,   Snail↑, 1,   TGF-β↓, 2,   TGF-β↑, 1,   TumCI?, 1,   TumCI↓, 22,   TumCI↑, 1,   TumCMig↓, 27,   TumMeta↓, 9,   Twist↓, 1,   Twist↑, 1,   TXNIP↓, 1,   Vim↓, 13,   Zeb1↓, 1,   ZEB2↑, 2,   α-SMA↓, 2,   β-catenin/ZEB1↓, 9,   p‑β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 6,   CD31/PECAM-1↑, 1,   eNOS↓, 1,   HIF-1↓, 1,   Hif1a↓, 10,   Hif1a↑, 1,   Hif1a↝, 1,   NO↑, 2,   VEGF↓, 11,   VEGFR2/KDR/Flk1↓, 1,   VM↓, 1,  

Barriers & Transport(tgid=15) ⓘ

ABCG1↓, 1,   CellMemb↓, 1,   CellMemb↑, 1,   GLUT1↓, 6,   GLUT2↓, 2,   MMP↓, 19,   MMP↑, 1,   MPT↓, 1,   SLC12A5↓, 1,   SVCT-2↝, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   CD44↓, 2,   CD8+↑, 1,   COX2/PTGS2↓, 2,   CXCL1↓, 1,   CXCL12↓, 1,   CXCR4↓, 2,   IL1↑, 1,   IL10↓, 2,   IL10↑, 1,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 2,   Imm↑, 1,   Inflam↓, 2,   LTA/TNF-β↓, 1,   M2 MC↑, 1,   NF-kB↓, 12,   NF-kB↑, 1,   NLRP3↓, 2,   p65↓, 2,   PD-L1↓, 1,   PD-L1↑, 1,   PSA↓, 3,   T-Cell↑, 1,   TCF↓, 2,   TNF-α↓, 1,   TNF-α↑, 1,   Treg lymp↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

TAMS↓, 1,  

Protein Aggregation(tgid=19) ⓘ

APP↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 3,   AR-FL↓, 1,   AR-V7↑, 1,   ER(estro)↓, 1,   ERα/ESR1↓, 1,   EstroRS/ERS↓, 1,   FKBP5↓, 1,   PPARα↑, 1,   PPARα↝, 1,   PPARγ↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 4,   ChemoSen↑, 20,   ChemoSen⇅, 1,   ChemoSen∅, 1,   CompStab↝, 1,   Dose↑, 1,   Dose↝, 9,   Dose∅, 5,   eff?, 1,   eff↓, 23,   eff↑, 20,   eff↝, 4,   eff∅, 1,   Half-Life↝, 1,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 4,   selectivity?, 1,   selectivity↓, 1,   selectivity↑, 36,   Synergy↑, 13,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT∅, 1,   AR↓, 3,   AST∅, 1,   BG↓, 1,   CA125↓, 1,   EGFR↓, 5,   ERα/ESR1↓, 1,   EstroRS/ERS↓, 1,   FOXM1↓, 1,   IL6↓, 2,   LDH↓, 1,   PD-L1↓, 1,   PD-L1↑, 1,   PSA↓, 3,   TP53↑, 1,   XIST↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 8,   AntiTum↑, 5,   cardioP↑, 2,   chemoP↑, 5,   hepatoP↑, 1,   K17↓, 1,   memory↑, 1,   neuroP↑, 2,   OS↑, 10,   QoL↑, 1,   radioP↑, 2,   RenoP↑, 1,   toxicity↓, 4,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 27,   TumW↓, 15,   Weight∅, 2,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,   GutMicro↑, 2,  
Total Targets: 460

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 7,   Catalase↓, 1,   GPx↓, 1,   GPx4↓, 1,   GSH↓, 1,   GSH↑, 3,   HO-1↓, 1,   HO-1↑, 3,   HO-1↝, 1,   Iron↓, 2,   i-Iron↑, 1,   ox-Keap1↑, 1,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↓, 3,   MDA↑, 1,   NRF2↓, 1,   NRF2↑, 6,   Prx4∅, 1,   ROS↓, 11,   ROS↑, 3,   ROS∅, 1,   SOD↓, 1,   SOD↑, 1,   SOD1↑, 2,   uricA↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,   NCOA4↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Acetyl-CoA↑, 1,   ALAT↑, 1,   ECAR↓, 1,   FASN↓, 1,   GlucoseCon↓, 1,   GlucoseCon↑, 1,   Glycolysis↓, 2,   Glycolysis↑, 1,   HK2↓, 3,   lactateProd↓, 1,   LDHA↓, 1,   LDL↓, 1,   NH3↓, 1,   PFK↓, 1,   PFK1↓, 1,   PKM2↓, 3,   SIRT1↑, 3,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 3,   ASC?, 1,   Casp1↓, 1,   Casp3↓, 1,   Ferroptosis↓, 1,   iNOS↓, 3,   p‑p38↓, 1,   Pyro?, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑Akt↑, 1,   p‑ERK↓, 1,   JAK2↑, 1,   MAPK↓, 1,   PKCδ↑, 1,   Sp1/3/4↓, 1,   Src↓, 1,   STAT3?, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↓, 1,   HDAC↓, 2,   other?, 1,   other↓, 1,   other↑, 1,   other↝, 5,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 2,   ER Stress↓, 4,   GRP78/BiP↓, 2,   PERK↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

IGF-1↑, 1,   TumCG∅, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   mt-ATPase↑, 1,   Ca+2↓, 1,   Ca+2↝, 1,   cal2↓, 1,   E-cadherin↑, 2,   EMT↓, 1,   EMT↑, 1,   F-actin↓, 1,   MMP9↑, 2,   MMPs↑, 1,   N-cadherin↓, 1,   Smad7↑, 1,   Snail↓, 1,   TIMP1↑, 1,   TumCMig↓, 1,   Vim↓, 2,   α-SMA↓, 2,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   angioG↑, 3,   eNOS↑, 1,   Hif1a↓, 2,   Hif1a↑, 2,   NO↓, 2,   TXA2↑, 1,   VEGF↓, 1,   VEGF↑, 2,  

Barriers & Transport(tgid=15) ⓘ

MMP↑, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL17↓, 2,   IL18↓, 1,   IL1β↓, 3,   IL22↓, 1,   IL6↓, 3,   Inflam↓, 9,   Inflam↑, 1,   NF-kB↓, 5,   NLRP3↓, 1,   PGE2↓, 1,   TNF-α↓, 4,  

Synaptic & Neurotransmission(tgid=18) ⓘ

Ach↑, 1,   ChAT↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   BioEnh↑, 1,   Dose↝, 2,   eff↑, 1,   Half-Life∅, 1,   MRP↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↑, 1,   ascitic↓, 1,   AST↑, 1,   BG↓, 1,   BUN↓, 1,   CEA↓, 1,   creat↓, 2,   IL6↓, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↑, 1,   cardioP↑, 2,   cognitive↑, 2,   GFR↑, 1,   hepatoP↓, 1,   hepatoP↑, 2,   memory↑, 2,   neuroP↑, 4,   OS↑, 1,   RenoP↑, 2,   toxicity↓, 14,   toxicity∅, 6,   Weight↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 1,   GutMicro↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 152

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page